OSE has announced its strategic plan for the next three years, which is designed to create multiple near-term catalysts. Importantly, it aims to extract maximum value from its lead proprietary candidates, Tedopi and lusvertikimab. For Tedopi, the registrational Phase III ARTEMIA trial in non-small
